Nature Reviews Rheumatology, Published online: 01 December 2025; doi:10.1038/s41584-025-01339-1Many of the current therapies for arthritis lack a targeted approach, limiting clinical benefits. Nanoparticle-based delivery systems have enabled more precise and efficient delivery of therapeutic agents, particularly nucleic acids. Studies in 2025 emphasize the promise of these strategies for the treatment of various forms of arthritis.

Nature Reviews Rheumatology, Published online: 05 December 2025; doi:10.1038/s41584-025-01340-8A new study uncovers how UBA1 mutations in VEXAS syndrome simultaneously promote myeloid inflammatory cell death and skew haematopoietic stem cells towards a myeloid lineage.

Immune-checkpoint agonists are a promising therapeutic approach for autoimmune disease. This Review discusses the immune-checkpoint receptors PD-1, BTLA and TIGIT as well as the preclinical and clinic...

Nature Reviews Rheumatology - Emerging evidence suggests a paradigm shift in viewing osteoarthritis (OA) as a systemic, bidirectional disease. This Review examines the current data supporting this...

Nature Reviews Rheumatology, Published online: 03 December 2025; doi:10.1038/s41584-025-01337-3Advances in artificial intelligence (AI) are transforming patient stratification in rheumatology. In 2025, three landmark studies demonstrated how multimodal AI approaches spanning clinical, molecular and longitudinal data can uncover distinct disease subtypes and predict therapeutic response, advancing the field towards precision rheumatology.

Nature Reviews Rheumatology, Published online: 03 December 2025; doi:10.1038/s41584-025-01332-8Emerging evidence suggests a paradigm shift in viewing osteoarthritis (OA) as a systemic, bidirectional disease. This Review examines the current data supporting this concept, outlines key challenges in research approaches, and proposes strategies to improve preclinical studies and clinical trial design.

Nature Reviews Rheumatology, Published online: 28 November 2025; doi:10.1038/s41584-025-01338-2T helper 17 cells that lose IL-17 expression drive inflammation in a mouse model of chronic rheumatoid arthritis.

Nature Reviews Rheumatology, Published online: 02 December 2025; doi:10.1038/s41584-025-01296-9Immune-checkpoint agonists are a promising therapeutic approach for autoimmune disease. This Review discusses the immune-checkpoint receptors PD-1, BTLA and TIGIT as well as the preclinical and clinical evidence for therapeutically targeting these receptors for the treatment of rheumatic diseases.

Nature Reviews Rheumatology, Published online: 27 November 2025; doi:10.1038/s41584-025-01329-3In this Consensus Statement, a Group for Research and Assessment of Psoriasis and Psoriatic Arthritis task force presents consensus definitions for two distinct states, complex-to-manage PsA and treatment-refractory PsA, with the aim of standardizing terminology, improving patient stratification and guiding clinical decision-making and future research.

Nature Reviews Rheumatology, Published online: 01 December 2025; doi:10.1038/s41584-025-01339-1Many of the current therapies for arthritis lack a targeted approach, limiting clinical benefits. Nanoparticle-based delivery systems have enabled more precise and efficient delivery of therapeutic agents, particularly nucleic acids. Studies in 2025 emphasize the promise of these strategies for the treatment of various forms of arthritis.

Nature Reviews Rheumatology, Published online: 26 November 2025; doi:10.1038/s41584-025-01335-5A nanobody that targets IL-17A and IL-17F has shown promise in a phase II study of patients with active psoriatic arthritis.

Nature Reviews Rheumatology, Published online: 26 November 2025; doi:10.1038/s41584-025-01328-4Cam morphology can cause intra-articular joint damage and lead to femoroacetabular impingement syndrome and eventually hip osteoarthritis. This Review explores the development and effect of cam morphology on femoroacetabular impingement syndrome and hip osteoarthritis, discussing relevant terminology, diagnostic approaches, pathophysiological insights and management strategies.

Nature Reviews Rheumatology, Published online: 24 November 2025; doi:10.1038/s41584-025-01334-6The results of the phase II DAHLIAS trial support the development of the neonatal Fc receptor blocker nipocalimab for the treatment of Sjögren disease.

Nature Reviews Rheumatology, Published online: 24 November 2025; doi:10.1038/s41584-025-01326-6This Review explores the complex relationship between obesity and psoriatic disease. The authors highlight the underlying mechanisms that drive this association and propose a comprehensive approach to managing obesity in individuals with psoriatic disease to improve overall disease management and therapeutic response.

Nature Reviews Rheumatology, Published online: 28 November 2025; doi:10.1038/s41584-025-01338-2T helper 17 cells that lose IL-17 expression drive inflammation in a mouse model of chronic rheumatoid arthritis.

Nature Reviews Rheumatology, Published online: 27 November 2025; doi:10.1038/s41584-025-01329-3In this Consensus Statement, a Group for Research and Assessment of Psoriasis and Psoriatic Arthritis task force presents consensus definitions for two distinct states, complex-to-manage PsA and treatment-refractory PsA, with the aim of standardizing terminology, improving patient stratification and guiding clinical decision-making and future research.

Nature Reviews Rheumatology, Published online: 26 November 2025; doi:10.1038/s41584-025-01335-5A nanobody that targets IL-17A and IL-17F has shown promise in a phase II study of patients with active psoriatic arthritis.

Nature Reviews Rheumatology, Published online: 19 November 2025; doi:10.1038/s41584-025-01321-xChildhood-onset SLE is characterized by high disease activity, severe organ damage and substantial treatment challenges. The authors of this Review provide an update on the advances in the understanding of the pathogenesis of childhood-onset SLE in the past decade, emphasizing the need for more research to improve outcomes.

Nature Reviews Rheumatology, Published online: 24 November 2025; doi:10.1038/s41584-025-01334-6The results of the phase II DAHLIAS trial support the development of the neonatal Fc receptor blocker nipocalimab for the treatment of Sjögren disease.

Nature Reviews Rheumatology, Published online: 24 November 2025; doi:10.1038/s41584-025-01326-6This Review explores the complex relationship between obesity and psoriatic disease. The authors highlight the underlying mechanisms that drive this association and propose a comprehensive approach to managing obesity in individuals with psoriatic disease to improve overall disease management and therapeutic response.

Nature Reviews Rheumatology, Published online: 18 November 2025; doi:10.1038/s41584-025-01330-wFindings reveal that inhibiting cytosolic phospholipase A2 in chondrocytes could be a potential therapeutic target for degenerative joint diseases.

Analysis of regional variations in the epidemiology of rheumatoid arthritis (RA) over the past 40 years indicates that the age-standardized incidence of RA has increased — and is expected to continue ...

Immune-mediated inflammatory diseases (IMIDs) are associated with cancer risk through mechanisms involving disrupted immune tolerance and dysregulated immune responses. Deng et al. investigated how th...

ANCA-associated vasculitis (AAV) includes three disease subtypes with partly overlapping clinical manifestations: granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA) and eosinophili...

This Review article provides an update on the pathophysiology, diagnosis and treatment of Takayasu arteritis. The authors emphasize the need for a multidisciplinary approach to the diagnosis and manag...